Tty Biopharm Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tty Biopharm Company Limited with three other
companies in this sector in Taiwan:
Tci Co Ltd
sales of 4.07 billion Taiwanese Dollars [US$131.86 million]
of which 65%
Formosa Laboratories, Inc
(2.54 billion Taiwanese Dollars [US$82.22 million]
of which 100%
was Active Pharmaceutical Ingredient), and
Pharmally International Holding Company Ltd
(4.30 billion Taiwanese Dollars [US$139.38 million]
of which 42%
was Glass Bottle).
Tty Biopharm Company Limited reported sales of 4.08 billion Taiwanese Dollars (US$132.07 million)
December of 2017.
increase of 8.5%
versus 2016, when the company's sales were 3.76 billion Taiwanese Dollars.
This was the third consecutive year of growth at Tty Biopharm Company Limited.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Tty Biopharm Company Limited had sales
of 4.02 billion Taiwanese Dollars.
Sales of Anti-Infection Drug saw an increase
that was more than double the company's growth rate: sales were up
58.2% in 2017, from
508.11 million Taiwanese Dollars to 803.70 million Taiwanese Dollars.
Not all segments of Tty Biopharm Company Limited experienced an increase in sales in 2017:
sales of Other fell 26.0% to 12.64 million Taiwanese Dollars.
(However, this segment's sales were only a very small portion of the company's overall sales).
Tty Biopharm Company Limited also experienced decreases in sales in
Cardiovascular and Gastrointestinal Drug (down 1.3% to 486.28 million Taiwanese Dollars)